High-Grade Cervical Squamous Intraepithelial Lesion (HSIL)
Conditions
Interventions
Experimental group (FUS treatment group):Preoperative localization of the lesion area, irradiating according to optimized parameters (such as 50s/100s/300s). Immediately after surgery, perform CKC con
Control group (CKC treatment group):Conventional cold-knife conization, with postoperative pathological examination.
Sponsors
Guangzhou Women and Children's Medical Center Liuzhou Hospital
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1.The cervical transformation zone is classified as Type I (fully visible) under colposcopy, with the lesion's extent and boundaries completely exposed. 2.Pathological confirmation of cervical HSIL via cervical biopsy, with negative endocervical curettage (ECC) results. 3.High-risk HPV infection confirmed by preoperative testing. 4.No prior cervical surgery or physical therapy within the last 3 months before enrollment. 5.Informed consent obtained, indicating the patient's understanding and voluntary agreement to participate in the study
Exclusion criteria
Exclusion criteria: 1.Type II-III cervical transformation zone under colposcopy (partially or completely invisible), with ill-defined lesion margins and extent. 2.Positive ECC (endocervical curettage) results, suggesting possible endocervical involvement. 3.Pathological suspicion of cervical cancer or glandular epithelial lesions. 4.History of cervical excision, cervical squamous intraepithelial lesions, or pelvic radiotherapy. 5.Active genital tract infections, including vaginitis, cervicitis, vulvitis, or pelvic inflammatory disease. 6.Severe systemic diseases, such as cardiac, hepatic, or renal dysfunction, diabetes, or immune disorders. 7.Pregnancy. 8.Coagulation disorders.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Coagulation necrosis area post-tissue ablation; | — |
Secondary
| Measure | Time frame |
|---|---|
| Apoptosis rate and survival rate of cervical cancer Caski cells (flow cytometry);Postoperative bleeding time; | — |
Countries
China
Contacts
Public ContactTao Hua
Guangzhou Women and Children's Medical Center Liuzhou Hospital
Outcome results
None listed